Sandoz posts steady FY24 results, cautious FY25 outlook, Biosimilars in focus

Sandoz posts steady FY24 results, cautious FY25 outlook, Biosimilars in focus#Sandoz #posts #steady #FY24 #results #cautious #FY25 #outlook #Biosimilars #focus